214 results about "Muscle mass" patented technology

Methods and systems for the treatment for ALS incorporating stem cells harvested from the subject to be treated. These stem cells may be genetically altered with the addition of several genes of interest. Then, the patient will receive systemic gene therapy for the muscles and directed specifically at motor neurons. In this multi-pronged treatment approach, the stem cells provide immune regulation and the regeneration of motor neurons. And, the new motor neurons carry the added genes, which are protective against motor neuron death from ALS. The systemic therapy increases the amount of genes, which further reduces the effects of ALS. Additional gene therapy administered in the muscle will be further protective of the axon, while maintaining muscle mass and function.

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

A composition for enhancing cellular energy that includes creatine, L-arginine-α-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.

Methods and devices for increasing revascularization in an ischemic heart and for reducing muscle mass or volume in congestive heart failure patients are described. The method includes using laser energy to create microchannels in the target tissue. The microchannels are separated from each other to maintain tissue that is untreated or undamaged by laser energy. Such undamaged tissue augments angiogenesis. The method also includes delivery of bioactive agents that are angiogenic. The apparatus simultaneously creates a plurality of microchannels that are separated from each other and thereby promote angiogenesis, revascularization and/or muscle reduction.

To accurately measure the muscle mass, body-fat ratio and/or other information of the subject, the human body is divided into nine segments including the trunk, right and left forearms, right and left upper arms, right and left thigh, and right and left crura. Four distal voltage-measuring points Pv are determined at the wrists and ankles, and four proximal voltage-measuring points Pv are determined at the elbows and knees. Four current-carrying electrodes and four measuring electrodes are used. First, the measuring electrodes are attached to distal points, and the impedances of four limbs and the trunk are measured. Then, the measuring electrodes are moved to proximal points, and the impedances of four limbs and the trunk are measured. From the measurement result, the measurement value is calculated for each segment. Then, using estimation formulae created by a regression analysis based on the data collected with an MRI, the body composition such as a muscle mass is estimated from the measurement values of the impedances and body specific information including the height, weight, etc.

Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I

wherein R¹, R^1a, R⁶, X^a, X^b and Y are as described herein.

The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.

The invention relates to methods and materials for enhancing muscle mass or for the treatment of muscle disease in a subject, comprising introducing a cell which has a lower than normal level of myostatin signalling, into the subject.

Methods for enhancing the quality of life of a senior or super senior animal by feeding the animal a composition comprising at least one omega-3 polyunsaturated fatty acid and various combinations of amino acids, minerals, and antioxidants in amounts effective to enhance alertness, improve vitality, protect cartilage, maintain muscle mass, enhance digestibility, and improve skin and pelage quality. Changes in expression of genes associated with several biological pathways induced in an animal by feeding it said composition are consistent with an enhanced quality of life.

Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy

Oligomers and polymer compositions are provided which comprise GHB and produce GHB after administration in vivo. Devices for the storage and delivery of these polymers and oligomers are also provided. These oligomers and polymer compositions are useful in a variety of applications. The compositions can be used therapeutically, for example, in the treatment of patients with narcolepsy, chronic schizophrenia, catatonic schizophrenia, atypical psychoses, chronic brain syndrome, neurosis, alcoholism, drug addiction and withdrawal, Parkinson's disease and other neuropharmacological illnesses, hypertension, ischemia, circulatory collapse, radiation exposure, cancer, and myocardial infarction. Other uses for the compositions include anesthesia induction, sedation, growth hormone production, heightened sexual desire, anorectic effects, euphoria, smooth muscle relaxation, muscle mass production, and sleep, including rapid eye movement sleep. In a still further embodiment, the oligomers and polymers may be used to produce absence seizures.

A versatile, functional training device of substantially elliptical shape and comprising a fluid weight that employs principles of unstable resistance as a means of increasing balance, stability, overall strength, core strength and proprioception while increasing lean muscle mass and burning calories. During operation, a user moves the device through a regimen of individualized movements, and the fluid weight moves and shifts inside the device, creating a instability at a point of resistance. The device comprises D-shaped handles with finger grooves adapted for maneuverability. The handles also may be filled with fluid to increase the weight and adaptability of the device across multiple activities and physical regimens. Measuring scales are provided on the device to measure the amount of fluid added to or removed from the device. The device may be transparent or translucent, and the fluid weight may be tinted to aid in visibility.

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and/or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

A multi-directional rolling fitness device is disclosed. The device can be used individually or as a pair with either the hands or the feet. The device comprises a handle assembly, which can also comprise a stirrup for the foot, a base unit and a plurality of ball-transfer units. By using a single or pair of these devices, a person can use their body weight to engage in a nearly unlimited number of upper and lower body exercises. The device's ball transfer contact points allow the unit to move in any direction across the floor during exercise repetitions, engaging complex muscle groups, increasing range of motion, and aiding in the development of muscle mass, strength and endurance.

The invention relates to methods to select animals, such as mammals, in particular, domestic animals such as breeding animals or animals destined for slaughter, for having desired genotypic or potential phenotypic properties, in particular, related to muscle mass and/or fat deposition or, in the case of mammals, to teat number. The invention provides a method for selecting an animal for having desired genotypic or potential phenotypic properties comprising testing the animal, a parent of the animal or its progeny for the presence of a nucleic acid modification affecting the activity of an evolutionary conserved CpG island, located in intron 3 of an IGF2 gene and/or for the presence of a nucleic acid modification affecting binding of a nuclear factor to an IGF2 gene.

The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal.

A nutritional composition is provided which has an effective prophylactic and/or improving effect for various symptoms of muscle mass decrease, decreased basal metabolism, low body temperature, suppression of obesity, suppression of visceral fat accumulation, hyperglycemia, hyperlipidemia and the like in elderly people. The nutritional composition can include n-3 fatty acid and one or more of free lysine, dipeptides containing lysine, and lysine salts, wherein the content of free lysine, dipeptides containing lysine, and/or lysine salts is 0.1 g-10.0 g per 100 kcal of the composition, and the content of the total amount of n-3 fatty acid is 0.17 g-5.00 g per 100 kcal of the composition.

Embodiments of the invention provide methods and systems to deform a computer-generated three-dimensional surface using a lattice of rigid bone segments driven by an interpolation algorithm to define a muscle. Such embodiments allow a realistic presentation of subdermal muscle mass. In one embodiment, each end of a curve, created by an interpolation function, is attached to a corresponding bone. One or more muscle segments are attached along the curve. The curve along with the attached muscle segments defines a muscle. As the bones move and rotate the curve is expanded or contracted due to the endpoints of the curve being fixed to distinct bones. The attached muscle segments will experience corresponding expansion and contraction thus providing a realistic presentation of skin deformation. For one embodiment, the position of each muscle segment is determined in reference to a standard Bezier interpolation function.

A muscle growth regulating factor includes polynucleotide and polypeptide sequences, promoter sequences, constructs comprising the sequences, and compositions for regulating muscle growth and treating diseases associated with muscle growth. The present sequences can be used in identifying animals with altered muscle mass, and for selective breeding programs to produce animals with altered muscle mass.